Biotech | December 17, 2021
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
Effectiveness of Covaxin against the Omicron variant is currently being studied
Effectiveness of Covaxin against the Omicron variant is currently being studied
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity
Subscribe To Our Newsletter & Stay Updated
